Rocket Lab's Neutron Delay and Lost NASA Contract Put the Spotlight on Execution Risk

Rocket Lab's flawless Electron launches contrast with Neutron uncertainty, Mars contract loss, and analyst target cuts, leaving shares near oversold.

The gap between what Rocket Lab achieves on the launch pad and what its share price reflects has rarely been wider. That tension — between a flawless operational record and mounting questions about the company's next growth chapter — is now the central debate for investors weighing the stock.

The company's 94th Electron mission lifted off last Wednesday, deploying the StriX radar satellite for Japanese operator Synspective and marking the 15th launch of 2026. The flight, dubbed "Owl Around The World," extended a perfect success rate across all Synspective missions to date. With 16 additional booked launches for Synspective through 2030, the small-launch business offers rare visibility, backed by a reported backlog of $2.36 billion.

The Neutron question hangs over the narrative

That operational reliability, however, stands in sharp contrast to the uncertainty surrounding Neutron, the larger reusable rocket designed to move Rocket Lab beyond the small-satellite niche and into direct competition with heavy-lift players. The company itself has cautioned that the window for a Neutron debut this year is narrowing, and market observers reported on Friday that the first flight could slip into 2027.

For a stock that has long traded on the promise of Neutron as a second growth engine, every delay pushes the earnings inflection point further out — and forces investors to reassess how much of the future is already priced in.

Adding to the pressure, NASA awarded a Mars communications contract worth roughly $700 million to Blue Origin instead of Rocket Lab. While not existential, the decision signals that Rocket Lab cannot assume it will win the largest government programs, even with a strong operational track record.

Divergent signals from insiders and institutions

The mixed sentiment is visible across different corners of the market. CFO Adam Spice sold 140,157 shares at an average price of $62.63, generating approximately $8.8 million, through a pre-arranged 10b5-1 plan. Such sales are routine and not inherently bearish, but they arrive at an awkward moment when the stock is already under pressure.

Institutions, meanwhile, have shown a different appetite. ARK Invest funds purchased roughly 504,799 shares worth about $31.6 million during the same period, a deliberate bet against the prevailing short-term skepticism. Berenberg also initiated coverage on September 2 with a buy rating and a price target of $83, adding a bullish voice to the debate.

Analysts trim targets but hold their ground

The analyst community reflects the same split personality. Bank of America lowered its price target from $115 to $110 on August 31, while Roth Capital cut its target from $130 to $110 on the same day — both maintaining buy recommendations. The pattern is consistent: conviction in the long-term story remains intact, but near-term execution risks are now being factored into valuations.

The stock closed Monday at €56.70, up 2.4 percent on the day, offering a modest reprieve after a month that erased 19 percent. Over twelve months, the shares remain 40 percent higher, evidence that the broader growth narrative has not been abandoned by longer-horizon investors. The current price sits roughly 58 percent below the 52-week high of €133.80, with a relative strength index of 38.6 suggesting the stock is approaching oversold conditions.

A stock caught between two stories

What the market is really grappling with is a question of identity. Rocket Lab can be valued as a dependable launch services provider with a steady Electron cadence and a growing backlog — or as an option on Neutron, where the share price will rise or fall with each concrete milestone announcement.

The Electron business generates today's cash flow and demonstrates what this company does best: reliable, repeatable launches. But Neutron determines the size of tomorrow's opportunity, and until a firm launch date materializes, the uncertainty will keep weighing on the stock. The recent analyst corrections suggest even the most optimistic observers are now modeling delays into their projections, even as they stop short of abandoning the thesis altogether.

For now, Rocket Lab sits at a crossroads where both the bulls and the bears can point to supporting evidence. The market, it seems, is still deciding which story deserves the higher premium.